Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus / 임상당뇨병
Journal of Korean Diabetes
;
: 142-148, 2019.
Artigo
em Coreano
| WPRIM
| ID: wpr-761491
ABSTRACT
For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated. Metformin must be considered as the first-line oral glucose-lowering therapy, but other drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor agonists, sulfonylureas, glinides, α-glucosidase inhibitors, and insulin can be considered based on patient circumstances. If the initial HbA1c level of a patient is ≥ 7.5% or the HbA1c target is not achieved within three months of initiating monotherapy, dual combination therapy can be considered. If the HbA1c target is not achieved within 3 months of initiating dual therapy, a third agent with a complementary mechanism of action can be added for triple combination therapy. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of SGLT-2 inhibitors in T2DM patients with cardiovascular risk factors have been incorporated into the updated recommendations.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fatores de Risco
/
Abandono do Hábito de Fumar
/
Dipeptidil Peptidase 4
/
Tiazolidinedionas
/
Terapia Nutricional
/
Diabetes Mellitus
/
Diabetes Mellitus Tipo 2
/
Alcoolismo
/
Peptídeo 1 Semelhante ao Glucagon
/
Hipoglicemiantes
Tipo de estudo:
Estudo de etiologia
/
Guia de Prática Clínica
/
Fatores de risco
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS